ATXI

Avenue Therapeutics, Inc.

0.20 USD
+0.01 (+4.84%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avenue Therapeutics, Inc. stock is down -44.29% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 November’s closed higher than October.

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.